Publications

1. Sekar A, Griffin R, Parikh SA, Genovese G, Robinson DP, Norman AD, Olson JE, Rabe KG, Hoel MS, Boddicker NJ, Hampel PJ, Kay NE, Cerhan JR, Braggio E, Hanson CA, Vachon CM, Shanafelt TD, Ebert BL, Slager SL. Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL). Blood Cancer J. 2024 Nov 6; 14 (1):193 Epub 2024 Nov 06
   View PubMed
2. Hagerstrand D, Oder B, Cortese D, Qu Y, Binzer-Panchal A, Osterholm C, Del Peso Santos T, Rabbani L, Asl HF, Skaftason A, Ljungstrom V, Lundholm A, Koutroumani M, Haider Z, Jylha C, Mollstedt J, Mansouri L, Plevova K, Agathangelidis A, Scarfo L, Armand M, Muggen AF, Kay NE, Shanafelt T, Rossi D, Orre LM, Pospisilova S, Barylyuk K, Davi F, Vesterlund M, Langerak AW, Lehtio J, Ghia P, Stamatopoulos K, Sutton LA, Rosenquist R. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia. Leukemia. 2024 Nov; 38 (11):2429-2442 Epub 2024 Sept 11
   View PubMed
3. Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S, Precancer Think Tank Team. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer. 2024 Nov; 24 (11):792-809 Epub 2024 Oct 01
   View PubMed
4. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2024 Sep 27 Epub 2024 Sept 27
   View PubMed
5. Welch BM, Parikh SA, Kay NE, Medina KL. Profound deficiencies in mature blood and bone marrow progenitor dendritic cells in Chronic Lymphocyticcytic Leukemia patients. Res Sq. 2024 Sep 27 Epub 2024 Sept 27
   View PubMed
6. Vallejo BA, Ansari A, Parikh SA, Achenbach SJ, Rabe KG, Norman AD, Olson JE, Kay NE, Braggio E, Hanson CA, Vachon CM, Cerhan JR, Baum CL, Shanafelt TD, Slager SL. Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis. J Clin Oncol. 2024 Sep 4; JCO2400332 Epub 2024 Sept 04
   View PubMed
7. Ruan GJ, Wu X, Gwin KA, Manske MK, Abeykoon JP, Bhardwaj V, Witter TL, Schellenberg MJ, Rabe KG, Kay NE, Parikh SA, Witzig TE. Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia. Haematologica. 2024 Sep 1; 109 (9):2884-2892 Epub 2024 Sept 01
   View PubMed
8. Shanafelt TD, Wang XV, Hanson CA, Paietta E, O'Brien MD, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang C, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane M, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Kay NE. Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912. Blood Adv. 2024 Aug 20 [Epub ahead of print]
   View PubMed
9. Sinha S, Guo R, Del Busso MD, Han W, Boysen J, Wellik LE, Ghosh AK, Kay NE. Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications. Br J Cancer. 2024 Aug; 131 (3):589-600 Epub 2024 June 17
   View PubMed
10. Wiedmeier-Nutor JE, McCabe CE, O'Brien DR, Jessen E, Bonolo de Campos C, Boddicker NJ, Griffin R, Allmer C, Rabe KG, Cerhan JR, Parikh SA, Kay NE, Yan H, Van Dyke DL, Slager SL, Braggio E. Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations. Cancers (Basel). 2024 Jul 3; 16 (13) Epub 2024 July 03
    View PubMed
11. Shao Y, Kay NE, Gale RP, Liang Y. Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia. Leukemia 2024 Jul; 38 (7):1469-1473 Epub 2024 June 01
    View PubMed
12. Bordini J, Lenzi C, Frenquelli M, Morabito A, Pseftogas A, Belloni D, Mansouri L, Tsiolas G, Perotta E, Ranghetti P, Gandini F, Genova F, Hagerstrand D, Gavriilidis G, Keisaris S, Pechlivanis N, Davi F, Kay NE, Langerak AW, Pospisilova S, Scarfo L, Makris A, Psomopoulos FE, Stamatopoulos K, Rosenquist R, Campanella A, Ghia P. IkappaBepsilon deficiency accelerates disease development in chronic lymphocytic leukemia. Leukemia. 2024 Jun; 38 (6):1287-1298 Epub 2024 Apr 04
    View PubMed
13. Kleinstern G, Boddicker NJ, O'Brien DR, Allmer C, Rabe KG, Norman AD, Griffin R, Yan H, Ma T, Call TG, Bruins L, Brown S, Bonolo de Campos C, Hanson CA, Leis JF, Ding W, Vachon CM, Kay NE, Oakes CC, Parker AS, Brander DM, Weinberg JB, Furman RR, Shanafelt TD, Cerhan JR, Parikh SA, Braggio E, Slager SL. Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis. Blood Adv. 2024 May 14; 8 (9):2118-2129
    View PubMed
14. Ripoll JG, Tulledge-Scheitel SM, Stephenson AA, Ford S, Pike ML, Gorman EK, Hanson SN, Juskewitch JE, Miller AJ, Zaremba S, Ovrom EA, Razonable RR, Ganesh R, Hurt RT, Fischer EN, Derr AN, Eberle MR, Larsen JJ, Carney CM, Theel ES, Parikh SA, Kay NE, Joyner MJ, Senefeld JW. Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19. mBio. 2024 May 8; 15 (5):e0040024 Epub 2024 Apr 11
    View PubMed
15. Abdelbaky SB, Giacopelli B, Rabe KG, Yamaguchi K, Wu YZ, Yan H, Shanafelt TD, Parikh SA, Ding W, Hampel PJ, Brown S, Cerhan JR, Vachon CM, Kay NE, Hanson CA, Parker AS, Braggio E, Slager SL, Oakes CC. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature. Blood. 2024 Apr 25; 143 (17):1752-1757
    View PubMed
16. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
    View PubMed
17. Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmuller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024 Jan 18; 143 (3):258-271
    View PubMed
18. Papazoglou D, Wang XV, Shanafelt TD, Lesnick CE, Ioannou N, De Rossi G, Herter S, Bacac M, Klein C, Tallman MS, Kay NE, Ramsay AG. Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial. Blood. 2024 Jan 4; 143 (1):57-63
    View PubMed
19. Kosydar SR, Parikh SA, Lester SC, Rabe KG, Ding W, Burlile JF, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Schwager SM, Slager SL, Kay NE, Call TG, Breen WG, Hampel PJ. Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment. Am J Hematol 2023 Nov; 98 (11):E318-E321 Epub 2023 Aug 24
    View PubMed
20. Senefeld JW, Gorman EK, Johnson PW, Moir ME, Klassen SA, Carter RE, Paneth NS, Sullivan DJ, Morkeberg OH, Wright RS, Fairweather D, Bruno KA, Shoham S, Bloch EM, Focosi D, Henderson JP, Juskewitch JE, Pirofski LA, Grossman BJ, Tobian AAR, Franchini M, Ganesh R, Hurt RT, Kay NE, Parikh SA, Baker SE, Buchholtz ZA, Buras MR, Clayburn AJ, Dennis JJ, Diaz Soto JC, Herasevich V, Klompas AM, Kunze KL, Larson KF, Mills JR, Regimbal RJ, Ripoll JG, Sexton MA, Shepherd JRA, Stubbs JR, Theel ES, van Buskirk CM, van Helmond N, Vogt MNP, Whelan ER, Wiggins CC, Winters JL, Casadevall A, Joyner MJ. Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. Mayo Clin Proc Innov Qual Outcomes. 2023 Oct; 7 (5):499-513 Epub 2023 Oct 10
    View PubMed
21. Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunol Res. 2023 Sep 01; 11(9):1222-1236.
    View PubMed
22. Boddicker NJ, Parikh SA, Norman AD, Rabe KG, Griffin R, Call TG, Robinson DP, Olson JE, Dispenzieri A, Rajkumar V, Kumar S, Kay NE, Hanson CA, Cerhan JR, Murray D, Braggio E, Shanafelt TD, Vachon CM, Slager SL. Relationship among three common hematological premalignant conditions. Leukemia 2023 Aug; 37 (8):1719-1722 Epub 2023 May 05
    View PubMed
23. Griffin R, Wiedmeier-Nutor JE, Parikh SA, McCabe CE, O'Brien DR, Boddicker NJ, Kleinstern G, Rabe KG, Bruins L, Brown S, Bonolo de Campos C, Ding W, Leis JF, Hampel PJ, Call TG, Van Dyke DL, Kay NE, Cerhan JR, Yan H, Slager SL, Braggio E. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023 Jul 11; 7 (13):3169-3179
    View PubMed
24. Tedeschi A, Ahn IE, Fraser GAM, Greil R, Munir T, Kay NE, Flinn IW, Lee S, Saifan C, Kearbey J, Patel S, Barrientos JC. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:461-463
    View PubMed
25. Passerini M, Ratishvili T, Monroe JM, Temesgen Z, Witzig TE, Kay NE, Kennedy RB, Parikh SA. Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2023 Apr; 64 (4):874-883 Epub 2023 Mar 12
    View PubMed
26. Bantilan KS, Kay NE, Parikh SA, Rabe KG, Call TG, Leis JF, Ding W, Slager SL, Soumerai JD, Roeker LE, Mato A, Zelenetz AD. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leuk Lymphoma. 2023 Feb; 64 (2):300-311 Epub 2022 Dec 12
    View PubMed
27. Welch BM, Manso BA, Gwin KA, Lothert PK, Parikh SA, Kay NE, Medina KL. Comparison of the blood immune repertoire with clinical features in chronic lymphocytic leukemia patients treated with chemoimmunotherapy or ibrutinib. Front Oncol. 2023; 13:1302038 Epub 2023 Dec 04
    View PubMed
28. Parry EM, Leshchiner I, Guieze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broseus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 Jan; 29 (1):158-169 Epub 2023 Jan 09
    View PubMed
29. Ripoll JG, Gorman EK, Juskewitch JE, Razonable RR, Ganesh R, Hurt RT, Theel ES, Stubbs JR, Winters JL, Parikh SA, Kay NE, Joyner MJ, Senefeld JW. Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. Blood Adv. 2022 Dec 13; 6 (23):5951-5955
    View PubMed
30. Yang S, Kay NE, Shi M, Hanson CA, Gale RP. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)? Leukemia. 2022 Nov; 36 (11):2743-2747 Epub 2022 Sept 13
    View PubMed
31. Slager SL, Parikh SA, Achenbach SJ, Norman AD, Rabe KG, Boddicker NJ, Olson JE, Kleinstern G, Lesnick CE, Call TG, Cerhan JR, Vachon CM, Kay NE, Braggio E, Hanson CA, Shanafelt TD. Progression and survival of MBL: a screening study of 10 139 individuals. Blood. 2022 Oct 13; 140 (15):1702-1709
    View PubMed
32. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
33. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
34. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022 Jul 14; 140 (2):112-120
    View PubMed
35. Wang Z, Yan H, Boysen JC, Secreto CR, Tschumper RC, Ali D, Guo Q, Zhong J, Zhou J, Gan H, Yu C, Jelinek DF, Slager SL, Parikh SA, Braggio E, Kay NE. B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells. Blood Cancer J. 2022 Jul 1; 12 (7):99 Epub 2022 July 01
    View PubMed
36. Kay NE, Hampel PJ, Van Dyke DL, Parikh SA. CLL update 2022: A continuing evolution in care. Blood Rev. 2022 Jul; 54:100930 Epub 2022 Jan 26
    View PubMed
37. Soof CM, Spektor TM, Parikh SA, Slager SL, Rabe KG, Call TG, Kenderian SS, Ding W, Muchtar E, Ghermezi M, Kay NE, Berenson JR. Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Exp Hematol. 2022 Jul; 111:32-40 Epub 2022 May 05
    View PubMed
38. Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022 Jun 30; 139 (26):3708-3721
    View PubMed
39. Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022 Jun; 36(6):1635-1645. Epub 2022 Apr 19.
    View PubMed
40. Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, Rabe KG, Vachon CM, Lesnick CE, Call TG, Olson JE, Cerhan JR, Kay NE, Hanson CA, Shanafelt TD, Slager SL. Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia. 2022 May; 36 (5):1404-1407 Epub 2022 Feb 15
    View PubMed
41. Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, Zhang W, Rassenti LZ, Kipps TJ, Slager SL, Kay NE, Lesnick C, Shanafelt TD, Ghia P, Scarfo L, Livak KJ, Kharchenko PV, Neuberg DS, Olsen LR, Fan J, Gohil SH, Wu CJ. Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 Apr 7; 139 (14):2252-2256
    View PubMed
42. Wang H, Tian S, Zhao Q, Blumenschein W, Yearley JH, Secreto CR, Sinha S, Call TG, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, Shi M, Van Dyke DL, Kay NE, Slager SL, Braggio E, Yan H, Ding W. Differential transcriptomic profiling in ibrutinib-naive versus ibrutinib-resistant Richter syndrome. Hematol Oncol 2022 Apr; 40 (2):302-306 Epub 2021 Dec 03
    View PubMed
43. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 Feb 15; 28 (4):603-608
    View PubMed
44. Kleinstern G, Larson MC, Ansell SM, Thompson CA, Nowakowski GS, Call TG, Robinson DP, Maurer MJ, Mwangi R, Feldman AL, Kay NE, Novak AJ, Habermann TM, Slager SL, Cerhan JR. Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiol Biomarkers Prev 2022 Feb; 31 (2):461-470 Epub 2021 Nov 15
    View PubMed
45. King RL, Gupta A, Kurtin PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Leis JF, Wang Y, Schwager SM, Slager SL, Kay NE, Koehler A, Ansell SM, Inwards DJ, Habermann TM, Shi M, Hanson CA, Howard MT, Parikh SA. Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J. 2022 Jan 28; 12 (1):18
    View PubMed
46. Kaufman M, Yan XJ, Li W, Ghia EM, Langerak AW, Rassenti LZ, Belessi C, Kay NE, Davi F, Byrd JC, Pospisilova S, Brown JR, Catherwood M, Davis Z, Oscier D, Montillo M, Trentin L, Rosenquist R, Ghia P, Barrientos JC, Kolitz JE, Allen SL, Rai KR, Stamatopoulos K, Kipps TJ, Neuberg D, Chiorazzi N. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:897280 Epub 2022 July 12
    View PubMed
47. Kleinstern G, Weinberg JB, Parikh SA, Braggio E, Achenbach SJ, Robinson DP, Norman AD, Rabe KG, Boddicker NJ, Vachon CM, Lesnick CE, Call TG, Brander DM, Rassenti LZ, Kipps TJ, Olson JE, Cerhan JR, Kay NE, Furman RR, Hanson CA, Shanafelt TD, Slager SL. Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. Leukemia. 2022 Jan; 36 (1):119-125 Epub 2021 July 20
    View PubMed
48. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
49. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio E, Paietta EM, O'Brien S, Barrientos JC, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Erba H, Stone R, Litzow MR, Tallman MS, Shanafelt TD, Kay NE. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Blood. 2021 Dec 30; 138 (26):2810-2827
    View PubMed
50. Yang S, Kay NE, Shi M, Ossenkoppele G, Walter RB, Gale RP. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? Leukemia 2021 Dec; 35 (12):3364-3370 Epub 2021 Sept 27
    View PubMed
51. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illes A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021 Nov 1; 39 (31):3441-3452 Epub 2021 July 26
    View PubMed
52. Sakemura R, Bansal A, Siegler EL, Hefazi M, Yang N, Khadka RH, Newsom AN, Hansen MJ, Cox MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Nevala WK, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Horvei P, Ruff MW, Parikh SA, Pandey MK, DeGrado TR, Suksanpaisan L, Kay NE, Peng KW, Russell SJ, Kenderian SS. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunol Res. 2021 Sep; 9(9):1035-1046. Epub 2021 Jul 08.
    View PubMed
53. Wang Y, Achenbach SJ, Rabe KG, Shanafelt TD, Call TG, Ding W, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Schwager SM, Cerhan JR, Slager SL, Kay NE, Parikh SA. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer J 2021 Aug 5; 11 (8):140 Epub 2021 Aug 05
    View PubMed
54. Liebow M, Larson MC, Thompson CA, Nowakowski GS, Call TG, Macon WR, Kay NE, Habermann TM, Slager SL, Cerhan JR. Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. Int J Cancer. 2021 Aug 1; 149 (3):535-545 Epub 2021 Mar 08
    View PubMed
55. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Schwager SM, Lesnick CE, Kleinstern G, Van Dyke D, Hanson CA, Braggio E, Slager SL, Shanafelt TD. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021 Jul 15; 138 (2):149-159
    View PubMed
56. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
57. Maiti GP, Sinha S, Mahmud H, Boysen J, Mendez MT, Vesely SK, Holter-Chakrabarty J, Kay NE, Ghosh AK. SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021 May 17; 11 (5):93
    View PubMed
58. Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, Kay NE, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021 May 10; 11 (5):86
    View PubMed
59. Tian S, Zhang H, Zhang P, Kalmbach M, Lee JH, Ordog T, Hampel PJ, Call TG, Witzig TE, Kay NE, Klee EW, Slager SL, Yan H, Ding W. Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. Sci Rep. 2021 Apr 15; 11 (1):8318
    View PubMed
60. Slager SL, Lanasa MC, Marti GE, Achenbach SJ, Camp NJ, Abbasi F, Kay NE, Vachon CM, Cerhan JR, Johnston JB, Call TG, Rabe KG, Kleinstern G, Boddicker NJ, Norman AD, Parikh SA, Leis JF, Banerji V, Brander DM, Glenn M, Ferrajoli A, Curtin K, Braggio E, Shanafelt TD, McMaster ML, Weinberg JB, Hanson CA, Caporaso NE. Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. Blood. 2021 Apr 15; 137 (15):2046-2056
    View PubMed
61. Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021 Apr 7; 29 (4):1529-1540 Epub 2021 Jan 01
    View PubMed
62. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
63. Sinha S, Secreto CR, Boysen JC, Lesnick C, Wang Z, Ding W, Call TG, Kenderian SJ, Parikh SA, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Upregulation of AXL and beta-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J 2021 Feb 18; 11 (2):37
    View PubMed
64. Whitaker JA, Parikh SA, Shanafelt TD, Kay NE, Kennedy RB, Grill DE, Goergen KM, Call TG, Kendarian SS, Ding W, Poland GA. The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine. 2021 Feb 12; 39 (7):1122-1130 Epub 2021 Jan 16
    View PubMed
65. Muchtar E, Kay NE, Parikh SA. Early intervention in asymptomatic chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2021 Feb; 19 (2):92-103
    View PubMed
66. Manso BA, Krull JE, Gwin KA, Lothert PK, Welch BM, Novak AJ, Parikh SA, Kay NE, Medina KL. Chronic lymphocytic leukemia B-cell-derived TNFalpha impairs bone marrow myelopoiesis. iScience. 2021 Jan 22; 24 (1):101994 Epub 2020 Dec 26
    View PubMed
67. Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021 Jan 15; 14 (1):17
    View PubMed
68. Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood. 2021 Jan 14; 137 (2):216-231
    View PubMed
69. Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, Kleinstern G, Olson JE, Norman AD, Rabe KG, Schwager SM, Call TG, Slager SL. Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). Leukemia 2021 Jan; 35 (1):239-244 Epub 2020 Mar 18
    View PubMed
70. Archibald WJ, Rabe KG, Kabat BF, Herrmann J, Ding W, Kay NE, Kenderian SS, Muchtar E, Leis JF, Wang Y, Chanan-Khan AA, Schwager SM, Koehler AB, Fonder AL, Slager SL, Shanafelt TD, Call TG, Parikh SA. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021 Jan; 100 (1):143-155 Epub 2020 June 01
    View PubMed
71. Kretzmer H, Biran A, Purroy N, Lemvigh CK, Clement K, Gruber M, Gu H, Rassenti L, Mohammad AW, Lesnick C, Slager SL, Braggio E, Shanafelt TD, Kay NE, Fernandes SM, Brown JR, Wang L, Li S, Livak KJ, Neuberg DS, Klages S, Timmermann B, Kipps TJ, Campo E, Gnirke A, Wu CJ, Meissner A. Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 Jan; 2 (1):54-69 Epub 2020 Dec 03
    View PubMed
72. Kleinstern G, Rishi A, Achenbach SJ, Rabe KG, Kay NE, Shanafelt TD, Ding W, Leis JF, Norman AD, Call TG, Cerhan JR, Parikh SA, Baum CL, Slager SL. Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 2020 Dec; 83 (6):1581-1589 Epub 2020 July 16
    View PubMed
73. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
74. Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA. The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020 Nov 1; 105 (11):2675-2678 Epub 2020 Nov 01
    View PubMed
75. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
76. Solman IG, Blum LK, Hoh HY, Kipps TJ, Burger JA, Barrientos JC, O'Brien S, Mulligan SP, Kay NE, Hillmen P, Byrd JC, Lal ID, Dean JP, Mongan A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2020 Oct; 97:106432 Epub 2020 Aug 11
    View PubMed
77. Yan H, Tian S, Kleinstern G, Wang Z, Lee JH, Boddicker NJ, Cerhan JR, Kay NE, Braggio E, Slager SL. Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. Hum Mol Genet. 2020 Sep 29; 29 (16):2761-2774
    View PubMed
78. Kleinstern G, O'Brien DR, Li X, Tian S, Kabat BF, Rabe KG, Norman AD, Yan H, Vachon CM, Boddicker NJ, Call TG, Parikh SA, Bruins L, Bonolo de Campos C, Leis JF, Shanafelt TD, Ding W, Cerhan JR, Kay NE, Slager SL, Braggio E. Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. Am J Hematol. 2020 Aug; 95 (8):906-917 Epub 2020 May 07
    View PubMed
79. Parikh SA, Gale RP, Kay NE. Chronic lymphocytic leukemia in 2020: a surfeit of riches? Leukemia. 2020 Aug; 34 (8):1979-1983 Epub 2020 May 11
    View PubMed
80. Sharman JP, Cocks K, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Davids MS, Kiselev P, Swern AS, Sullivan K, Gharibo MM, Flick ED, Trigg A, Mato A. Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect((R)) CLL Registry. EJHaem. 2020 Jul; 1 (1):188-198 Epub 2020 July 26
    View PubMed
81. Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe KG, Degan M, Steffan A, Polesel J, Santinelli E, Innocenti I, Cutrona G, D'Arena G, Pozzato G, Zaja F, Chiarenza A, Rossi D, Di Raimondo F, Laurenti L, Gentile M, Morabito F, Neri A, Ferrarini M, Fegan CD, Pepper CJ, Del Poeta G, Parikh SA, Kay NE, Gattei V. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica. 2020 Jun; 105 (6):1613-1620 Epub 2019 Oct 03
    View PubMed
82. Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med. 2020 May; 9 (10):3390-3399 Epub 2020 Mar 18
    View PubMed
83. Mato A, Nabhan C, Lamanna N, Kay NE, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Swern AS, Sullivan K, Flick ED, Gressett Ussery SM, Gharibo M, Kiselev P, Sharman JP. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 Apr 14; 4 (7):1407-1418
    View PubMed
84. Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020 Mar; 105 (3):765-773 Epub 2019 June 13
    View PubMed
85. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
86. Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA. The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica. 2020 Jan 23 [Epub ahead of print]
    View PubMed
87. Kay NE, Hanson CA. B-cell prolymphocytic leukemia has 3 subsets. Blood 2019 Nov 21; 134 (21):1777-1778
    View PubMed
88. Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019 Nov; 60 (11):2712-2719 Epub 2019 Apr 24
    View PubMed
89. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood. 2019 Aug 22; 134 (8):688-698 Epub 2019 July 10
    View PubMed
90. Clay-Gilmour AI, Rishi AR, Goldin LR, Greenberg-Worisek AJ, Achenbach SJ, Rabe KG, Maurer MJ, Kay NE, Shanafelt TD, Call TG, Brice Weinberg J, Camp NJ, Cerhan JR, Leis J, Norman A, Murray DL, Vincent Rajkumar S, Caporaso NE, Landgren O, McMaster ML, Slager SL, Vachon CM. Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer J. 2019 Aug 5; 9 (8):59 Epub 2019 Aug 05
    View PubMed
91. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019 Aug 1; 381 (5):432-443
    View PubMed
92. Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia 2019 Aug; 33 (8):2111-2115 Epub 2019 Mar 14
    View PubMed
93. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul; 6 (7):e366-e374 Epub 2019 May 17
    View PubMed
94. Manso BA, Zhang H, Mikkelson MG, Gwin KA, Secreto CR, Ding W, Parikh SA, Kay NE, Medina KL. Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. Leukemia. 2019 Mar; 33 (3):638-652 Epub 2018 Oct 05
    View PubMed
95. Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. Am J Hematol. 2019 Mar; 94 (3):338-345 Epub 2019 Jan 08
    View PubMed
96. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7):697-709 Epub 2018 Nov 21
    View PubMed
97. Tschumper RC, Shanafelt TD, Kay NE, Jelinek DF. Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. Oncotarget. 2019 Jan 1; 10 (1):60-75 Epub 2019 Jan 01
    View PubMed
98. Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). Acta Haematol. 2019; 142 (4):224-232 Epub 2019 July 23
    View PubMed
99. Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, Secreto CR, Call T, Shanafelt TD, Leis JF, Warner SL, Bearss DJ, Ghosh AK, Kay NE. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 2018 Dec 14; 9 (98):37173-37184
    View PubMed
100. Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P. Improvement in parameters of hematologic and immunologic function and patient well-being in the phase iii resonate study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma Clinical Lymphoma Myeloma & Leukemia. 2018 Dec; 18 (12):803-13.e7
     
101. Barrientos JC, O'Brien S, Brown JR, Kay NE, Reddy NM, Coutre S, Tam C, Mulligan S, Jaeger U, Devereux S, Pocock C, Robak T, Schuster SJ, Schuh A, Gill D, Bloor A, Dearden C, Moreno C, Cull G, Hamblin M, Jones JA, Eckert K, Solman IG, Suzuki S, Hsu E, James DF, Byrd JC, Hillmen P. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Dec; 18 (12):803-813.e7 Epub 2018 Aug 18
     View PubMed
102. Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA. Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. Br J Haematol. 2018 Nov; 183 (3):421-427 Epub 2018 Aug 16
     View PubMed
103. Durani U, Go RS, Kay NE. Immune-mediated hemolytic anemia and thrombocytopenia in clonal B-cell disorders: a review. Clin Adv Hematol Oncol. 2018 Oct; 16 (10):670-676
     View PubMed
104. Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study. Leuk Lymphoma. 2018 Oct; 59 (10):2327-2335 Epub 2018 Feb 07
     View PubMed
105. Gomes J, Lucien F, Cooper TT, Kim Y, Williams KC, Liao X, Kaufman L, Lagugne-Labarthet F, Kenyon O, Boysen J, Kay NE, McIntyre CW, Leong HS. Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity. Thromb Haemost. 2018 Sep; 118 (9):1612-1624 Epub 2018 Aug 15
     View PubMed
106. Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL. Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood. 2018 Jun 7; 131 (23):2541-2551 Epub 2018 Apr 19
     View PubMed
107. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica 2018 Jun; 103 (6):e237-e240 Epub 2018 Feb 01
     View PubMed
108. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica. 2018 Jun; 103(6):e237-e240. Epub 2018 Feb 01.
     View PubMed
109. Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD. Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2018 Apr; 11 (4):337-349 Epub 2018 Feb 26
     View PubMed
110. Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 Feb; 18 (2):114-124.e2 Epub 2017 Dec 06
     View PubMed
111. Molica S, Giannarelli D, Mirabelli R, Levato L, Kay NE, Shanafelt TD. Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. Blood 2018 Jan 18; 131 (3):365-368 Epub 2017 Oct 30
     View PubMed
112. Brown JR, Kay NE. Reply to S. Opat et al. J Clin Oncol 2017 Dec 20; 35 (36):4094-4095 Epub 2017 Nov 03
     View PubMed
113. Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017 Dec 1; 46 (6):1753-1754i
     View PubMed
114. Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. Am J Hematol. 2017 Dec; 92 (12):1362-1369 Epub 2017 Oct 19
     View PubMed
115. Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017 Nov 28; 1 (25):2433-2443
     View PubMed
116. Brown JR, Kay NE. Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 Sep 10; 35 (26):2989-2992 Epub 2017 July 25
     View PubMed
117. Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017 Aug; 178 (3):394-402 Epub 2017 June 04
     View PubMed
118. Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol. 2017 Aug; 92 (8):759-763 Epub 2017 June 01
     View PubMed
119. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 2017 Jul; 58 (7):1630-1639 Epub 2016 Nov 25
     View PubMed
120. Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017 Jul; 178 (1):99-105 Epub 2017 Apr 07
     View PubMed
121. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
     View PubMed
122. Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma. 2017 Jun; 58 (6):1376-1383 Epub 2016 Nov 08
     View PubMed
123. Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017 Jun; 31 (6):1348-1354 Epub 2017 Jan 24
     View PubMed
124. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1; 129 (22):2971-2979 Epub 2017 Mar 30
     View PubMed
125. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. 2017 Apr 1; 77 (7):1510-1541
     View PubMed
126. Boysen J, Nelson M, Magzoub G, Maiti GP, Sinha S, Goswami M, Vesely SK, Shanafelt TD, Kay NE, Ghosh AK. Dynamics of microvesicle generation in B-cell chronic lymphocytic leukemia: implication in disease progression. Leukemia. 2017 Feb; 31 (2):350-360 Epub 2016 Aug 02
     View PubMed
127. Strati P, Chaffee KG, Achenbach SJ, Slager SL, Leung N, Call TG, Ding W, Parikh SA, Kay NE, Shanafelt TD. Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. Haematologica 2017 Jan; 102 (1):e22-e25 Epub 2016 Sept 15
     View PubMed
128. Barrio S, Shanafelt TD, Ojha J, Chaffee KG, Secreto C, Kortum KM, Pathangey S, Van-Dyke DL, Slager SL, Fonseca R, Kay NE, Braggio E. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017 Jan; 31 (1):170-176 Epub 2016 June 14
     View PubMed
129. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood. 2016 Dec 22; 128 (25):2931-2940 Epub 2016 Nov 04
     View PubMed
130. Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect((R)) chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016 Dec; 175 (5):892-903 Epub 2016 Nov 08
     View PubMed
131. Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 2016 Nov 29; 7 (48):78269-78280
     View PubMed
132. Molica S, Shanafelt TD, Giannarelli D, Gentile M, Mirabelli R, Cutrona G, Levato L, Di Renzo N, Di Raimondo F, Musolino C, Angrilli F, Fama A, Recchia AG, Chaffee KG, Neri A, Kay NE, Ferrarini M, Morabito F. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016 Nov; 91 (11):1090-1095 Epub 2016 Aug 08
     View PubMed
133. Kay NE, Sassoon T, Secreto C, Sinha S, Shanafelt TD, Ghosh AK, Arbiser JL. Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2016 Oct; 57 (10):2409-16 Epub 2016 May 17
     View PubMed
134. Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Sep; 3 (9):e407-14 Epub 2016 Aug 01
     View PubMed
135. Friedman DR, Sibley AB, Owzar K, Chaffee KG, Slager S, Kay NE, Hanson CA, Ding W, Shanafelt TD, Weinberg JB, Wilcox RA. Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. Am J Hematol. 2016 Jul; 91 (7):687-91 Epub 2016 Apr 24
     View PubMed
136. Nabhan C, Chaffee KG, Slager SL, Galanina N, Achenbach SJ, Schwager SM, Kay NE, Shanafelt TD. Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. Am J Hematol. 2016 Jul; 91 (7):677-80 Epub 2016 Apr 24
     View PubMed
137. Sinha S, Boysen J, Nelson M, Warner SL, Bearss D, Kay NE, Ghosh AK. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells. Leukemia 2016 Jun; 30 (6):1431-6 Epub 2015 Nov 24
     View PubMed
138. Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 2016 Jun; 30 (6):1440-3 Epub 2015 Dec 09
     View PubMed
139. Van Dyke DL, Werner L, Rassenti LZ, Neuberg D, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol. 2016 Apr; 173 (1):105-13 Epub 2016 Feb 05
     View PubMed
140. Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, Nieters A, Kelly RS, Smedby KE, Monnereau A, Cozen W, Cox A, Wang SS, Lan Q, Teras LR, Machado M, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Vajdic CM, Cocco P, Zhang Y, Giles GG, Zeleniuch-Jacquotte A, Lawrence C, Montalvan R, Burdett L, Hutchinson A, Ye Y, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Cunningham JM, Allmer C, Hjalgrim H, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Arnett DK, Zhi D, Leach JM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Sala N, Casabonne D, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Chaffee KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Leis JF, Weinberg JB, Caporaso NE, Norman AD, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RCH, Travis RC, Southey MC, Milne RL, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Villano DJ, Maria A, Spinelli JJ, Gascoyne RD, Connors JM, Bertrand KA, Giovannucci E, Kraft P, Kricker A, Turner J, Ennas MG, Ferri GM, Miligi L, Liang L, Ma B, Huang J, Crouch S, Park JH, Chatterjee N, North KE, Snowden JA, Wright J, Fraumeni JF, Offit K, Wu X, de Sanjose S, Cerhan JR, Chanock SJ, Rothman N, Slager SL. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun. 2016 Mar 9; 7:10933 Epub 2016 Mar 09
     View PubMed
141. Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, Kay NE, Slager SL, Shanafelt TD. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia. 2016 Feb; 30 (2):331-6 Epub 2015 Aug 27
     View PubMed
142. Tsukamoto S, Huang Y, Kumazoe M, Lesnick C, Yamada S, Ueda N, Suzuki T, Yamashita S, Kim YH, Fujimura Y, Miura D, Kay NE, Shanafelt TD, Tachibana H. Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. Mol Cancer Ther. 2015 Oct; 14 (10):2303-12 Epub 2015 Aug 11
     View PubMed
143. Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015 Sep 1; 121 (17):2883-91 Epub 2015 Apr 30
     View PubMed
144. Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD. Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica. 2015 Sep; 100 (9):1180-8 Epub 2015 June 18
     View PubMed
145. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine. 2015 Jun; 2 (6):572-82 Epub 2015 Apr 29
     View PubMed
146. Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clin Cancer Res. 2015 May 1; 21 (9):2115-26 Epub 2015 Feb 11
     View PubMed
147. Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, Chanan-Khan AA, Parikh SA, Slager SL, Kay NE, Call TG. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J Oncol Pract. 2015 May; 11 (3):252-8 Epub 2015 Mar 24
     View PubMed
148. Ojha J, Secreto CR, Rabe KG, Van Dyke DL, Kortum KM, Slager SL, Shanafelt TD, Fonseca R, Kay NE, Braggio E. Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol 2015 May; 169 (3):445-8 Epub 2014 Nov 10
     View PubMed
149. Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015 Apr; 90 (4):334-8 Epub 2015 Jan 30
     View PubMed
150. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015 Jan 22; 125(4):658-67. Epub 2014 Dec 01.
     View PubMed
151. Ojha J, Ayres J, Secreto C, Tschumper R, Rabe K, Van Dyke D, Slager S, Shanafelt T, Fonseca R, Kay NE, Braggio E. Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. Blood. 2015 Jan 15; 125 (3):492-8 Epub 2014 Nov 06
     View PubMed
152. Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A. The HELIOS trial protocol: A Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Fut Oncol. 2015; 11(1):51-9.
     
153. Kumazoe M, Tsukamoto S, Lesnick C, Kay NE, Yamada K, Shanafelt TD, Tachibana H. Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cells. Br J Haematol. 2015; 168(4):610-3.
     View PubMed
154. Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, Slager S, Fonseca R, Shanafelt T, Kay N, Braggio E. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia 2014 Dec; 28 (12):2395-8 Epub 2014 July 18
     View PubMed
155. Wettstein PJ, Borson ND, Kay NE. A novel method for analysis of human T cell repertoires by real-time PCR. J Immunol Methods. 2014 Oct; 412:24-34 Epub 2014 June 28
     View PubMed
156. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood. 2014 Jul 3; 124 (1):42-8 Epub 2014 May 27
     View PubMed
157. Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Dohner H, Jager U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3; 124 (1):49-62 Epub 2014 May 05
     View PubMed
158. Whitaker JA, Shanafelt TD, Poland GA, Kay NE. Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014 Jul; 12 (7):440-50
     View PubMed
159. Call TG, Norman AD, Hanson CA, Achenbach SJ, Kay NE, Zent CS, Ding W, Cerhan JR, Rabe KG, Vachon CM, Hallberg EJ, Shanafelt TD, Slager SL. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. Cancer. 2014 Jul 1; 120 (13):2000-5 Epub 2014 Apr 07
     View PubMed
160. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014 Mar 13; 123 (11):1647-57 Epub 2014 Jan 13
     View PubMed
161. Ratterman M, Kruczek K, Sulo S, Shanafelt TD, Kay NE, Nabhan C. Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. Leuk Res. 2014 Mar; 38(3):299-303. Epub 2013 Sep 6
     View PubMed
162. Laurie CC, Laurie CA, Smoley SA, Carlson EE, Flinn I, Fridley BL, Greisman HA, Gribben JG, Jelinek DF, Nelson SC, Paietta E, Schaid D, Sun Z, Tallman MS, Weinshilboum R, Kay NE, Shanafelt TD. Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. Cancer Genet. 2014 Jan-Feb; 207 (1-2):19-30 Epub 2014 Jan 17
     View PubMed
163. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, De Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371:213-23.
     View PubMed
164. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Schwager SM, Bowen DA, Conte M, Jelinek DF, Slager SL, Shanafelt TD. Chronic lymphocytic leukemia in young (View PubMed
165. Parikh SA, Kay NE, Shanafelt TD. Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. Clin Adv Hematol Oncol. 2013 Nov; 11(11):720-9.
     View PubMed
166. Shanafelt T, Lanasa MC, Call TG, Beaven AW, Leis JF, LaPlant B, Bowen D, Conte M, Jelinek DF, Hanson CA, Kay NE, Zent CS. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). Cancer. 2013 Nov 1; 119 (21):3788-96 Epub 2013 Aug 06
     View PubMed
167. Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C, Lerner S, Sharman J, Grinblatt D, Flinn IW, Kozloff M, Swern AS, Street TK, Sullivan KA, Harding G, Khan ZM. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer. 2013 Oct; 21(10):2853-60. Epub 2013 Jun 08.
     View PubMed
168. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12; 122(11):1891-9. Epub 2013 Jul 02.
     View PubMed
169. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013 Sep; 162 (6):774-82 Epub 2013 July 11
     View PubMed
170. Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):467-76.
     View PubMed
171. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, Cozen W, Monnereau A, Wang SS, Kelly RS, Lan Q, Teras LR, Chatterjee N, Chung CC, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Armstrong BK, Cocco P, Zhang Y, Severi G, Zeleniuch-Jacquotte A, Lawrence C, Burdette L, Yuenger J, Hutchinson A, Jacobs KB, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Wang AH, Smedby KE, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Jones B, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Holly EA, Smith MT, Jackson RD, Tinker LF, Benavente Y, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Leis JF, Cunningham JM, Weinberg JB, Morrison VA, Caporaso NE, Norman AD, Linet MS, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RC, Travis RC, Giles GG, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Offit K, Zelenetz A, Klein RJ, Spinelli JJ, Bertrand KA, Laden F, Giovannucci E, Kraft P, Kricker A, Turner J, Vajdic CM, Ennas MG, Ferri GM, Miligi L, Liang L, Sampson J, Crouch S, Park JH, North KE, Cox A, Snowden JA, Wright J, Carracedo A, Lopez-Otin C, Bea S, Salaverria I, Martin-Garcia D, Campo E, Fraumeni JF Jr, de Sanjose S, Hjalgrim H, Cerhan JR, Chanock SJ, Rothman N, Slager SL. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013 Aug; 45(8):868-76. Epub 2013 Jun 16.
     View PubMed
172. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013 May 16; 121 (20):4137-41 Epub 2013 Mar 14
     View PubMed
173. Slager SL, Achenbach SJ, Asmann YW, Camp NJ, Rabe KG, Goldin LR, Call TG, Shanafelt TD, Kay NE, Cunningham JM, Wang AH, Weinberg JB, Norman AD, Link BK, Leis JF, Vachon CM, Lanasa MC, Caporaso NE, Novak AJ, Cerhan JR. Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes. Cancer Epidemiol Biomarkers Prev. 2013 Mar; 22 (3):461-6 Epub 2013 Jan 10
     View PubMed
174. Zent CS, Wu W, Bowen DA, Hanson CA, Pettinger AM, Shanafelt TD, Kay NE, Leis JF, Call TG. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Leuk Lymphoma. 2013 Mar; 54 (3):476-82 Epub 2012 Aug 22
     View PubMed
175. Shanafelt TD, Call TG, Zent CS, Leis JF, LaPlant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2013 Jan 15; 119 (2):363-70 Epub 2012 July 03
     View PubMed
176. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Ranjan Patra C, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE, Mukhopadhyay D. Correction: potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology. 2013; 11(1):23. Epub 2013 Jul 1
     View PubMed
177. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One. 2013; 8 (12):e83830 Epub 2013 Dec 23
     View PubMed
178. Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, Hanson CA, Slager SL, Shanafelt TD. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls. Leukemia. 2013 Jan; 27 (1):136-41 Epub 2012 July 11
     View PubMed
179. McDonnell SK, Riska SM, Klee EW, Thorland EC, Kay NE, Thibodeau SN, Parker AS, Eckel-Passow JE. Experimental designs for array comparative genomic hybridization technology. Cytogenet Genome Res. 2013; 139 (4):250-7 Epub 2013 Mar 27
     View PubMed
180. Braggio E, Fonseca R, Kay NE. CGH protocols: chronic lymphocytic leukemia. Methods Mol Biol. 2013; 973:87-98.
     View PubMed
181. Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. Adv Exp Med Biol. 2013; 792:215-39
     View PubMed
182. Slager SL, Camp NJ, Conde L, Shanafelt TD, Achenbach SJ, Rabe KG, Kay NE, Novak AJ, Call TG, Bracci PM, Sille FM, Sanchez S, Akers NK, Cunningham JM, Serie DJ, McDonnell SK, Leis JF, Wang AH, Weinberg JB, Glenn M, Link B, Vachon CM, Lanasa MC, Skibola CF, Cerhan JR. Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. Br J Haematol. 2012 Dec; 159 (5):572-6 Epub 2012 Oct 01
     View PubMed
183. Cerhan JR, Fredericksen ZS, Novak AJ, Ansell SM, Kay NE, Liebow M, Dogan A, Cunningham JM, Wang AH, Witzig TE, Habermann TM, Asmann YW, Slager SL. A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21 (10):1799-806 Epub 2012 Aug 21
     View PubMed
184. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, Wiestner A, Kipps TJ. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012 Aug 10; 30(23):2820-2. Epub 2012 Jul 09.
     View PubMed
185. Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, Halperin E, Lanasa MC, Cunningham JM, Leis JF, Morrison VA, Spector LG, Vachon CM, Shanafelt TD, Strom SS, Camp NJ, Weinberg JB, Matutes E, Caporaso NE, Wade R, Dyer MJ, Dearden C, Cerhan JR, Catovsky D, Houlston RS. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood. 2012 Jul 26; 120 (4):843-6 Epub 2012 June 13
     View PubMed
186. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Buhler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Dohner H, Heerema NA, Marcucci G, Plass C, Byrd JC. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012 Jul 10; 30(20):2483-91. Epub 2012 May 07.
     View PubMed
187. Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 2012 Jul; 26 (7):1698-701 Epub 2012 Jan 20
     View PubMed
188. Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Cancer. 2012 Apr 1; 118 (7):1827-37 Epub 2011 Aug 26
     View PubMed
189. Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, Weaver AL, Call TG. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012 Mar 10; 30 (8):843-9 Epub 2012 Feb 13
     View PubMed
190. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay NE, Witzig TE, Weiner GJ. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb; 53 (2):211-7 Epub 2011 Sept 19
     View PubMed
191. Kay NE. Predicting clinical outcome in B-chronic lymphocytic leukemia. Am Soc Clin Oncol Educ Book. 2012; 394-8
     View PubMed
192. Braggio E, Kay N, Van Wier S, Tschumper RC, Smoley SA, Eckel-Passow JE, Sassoon T, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Longitudinal genome wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Blood. 2011 Nov 18; 118(21):1223-4.
     
193. Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol. 2011 Oct; 155 (1):53-64 Epub 2011 July 12
     View PubMed
194. Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 2011 Sep 8; 118 (10):2821-6 Epub 2011 July 15
     View PubMed
195. Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE, Kay NE, Hanson CA, Rabe KG, Achenbach SJ, Goldin LR, Camp NJ, Goodman BK, Vachon CM, Spector LG, Rassenti LZ, Leis JF, Gockerman JP, Strom SS, Call TG, Glenn M, Cerhan JR, Levesque MC, Weinberg JB, Caporaso NE. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia. 2011 Sep; 25(9):1459-66. Epub 2011 May 27.
     View PubMed
196. Zent CS, Kay NE. Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma. 2011 Aug; 52 (8):1425-34 Epub 2011 June 08
     View PubMed
197. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Leach S, Spinelli JJ, Smith MT, Chanock SJ, Padyukov L, Alfredsson L, Klareskog L, Glimelius B, Melbye M, Liu ET, Adami HO, Humphreys K, Liu J. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011 Apr; 7(4):e1001378. Epub 2011 Apr 21.
     View PubMed
198. Nabhan C, Dalal N, Mehta J, Kay NE. Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leuk Lymphoma. 2011 Mar; 52(3):374-86.
     View PubMed
199. Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, Kay NE. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011 Feb 10; 117 (6):1928-37 Epub 2010 Dec 06
     View PubMed
200. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, Camp NJ, Glenn M, Kay NE, Cunningham JM, Hanson CA, Marti GE, Weinberg JB, Morrison VA, Link BK, Call TG, Caporaso NE, Cerhan JR. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011 Feb 10; 117 (6):1911-6 Epub 2010 Dec 03
     View PubMed
201. Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, Weiner GJ, Call TG, Link BK, Zent CS, Kay NE, Hanson CA, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011 Feb 3; 117 (5):1492-8 Epub 2010 Nov 03
     View PubMed
202. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell'Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 5; 305(1):59-67.
     View PubMed
203. Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. PLoS One. 2011; 6 (10):e26056 Epub 2011 Oct 06
     View PubMed
204. Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, Cunningham JM, Shanafelt TD, Ansell SM, Call TG, Witzig TE, Slager SL, Liebow M. Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidemiol Genet. 2011; 2(2):95-113. Epub 2011 Apr 05.
     View PubMed
205. O'Brien S, Kay NE. Maintenance therapy for B-chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2011 Jan; 9(1):22-31.
     View PubMed
206. Nabhan C, Kay NE. The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. Clin Med Insights Oncol. 2011; 5:45-53. Epub 2011 Mar 24.
     View PubMed
207. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec; 203 (2):161-8
     View PubMed
208. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec; 203(2):141-8.
     View PubMed
209. Heerema NA, Byrd JC, Dal Cin, Dell' Aquila, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec; 203(2):134-40.
     View PubMed
210. Shanafelt T, Zent C, Byrd J, Erlichman C, Laplant B, Ghosh A, Call T, Villalona-Calero M, Jelinek D, Bowen D, Laumann K, Wu W, Hanson C, Kay N. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Dec; 51 (12):2222-9 Epub 2010 Nov 05
     View PubMed
211. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, Habermann TM, Slager SL, Cerhan JR. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2847-58. Epub 2010 Sep 20.
     View PubMed
212. Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, Jelinek DF, Kay NE. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010 Oct 21; 116 (16):2984-93 Epub 2010 July 06
     View PubMed
213. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, Slager SL, Kay NE, Jelinek DF. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood. 2010 Oct 21; 116 (16):2975-83 Epub 2010 July 01
     View PubMed
214. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Jelinek DF, Reinalda MS, Schwager SM, Bowen DA, Slager SL, Hanson CA, Call TG. Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer. 2010 Oct 15; 116 (20):4777-87
     View PubMed
215. Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010 Oct; 151(2):152-8. Epub 2010 Aug 25.
     View PubMed
216. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Becker N, Benavente Y, Boffetta P, Brennan P, Butterbach K, Cocco P, Foretova L, Maynadie M, de Sanjose S, Staines A, Spinelli JJ, Achenbach SJ, Call TG, Camp NJ, Glenn M, Caporaso NE, Cerhan JR, Cunningham JM, Goldin LR, Hanson CA, Kay NE, Lanasa MC, Leis JF, Marti GE, Rabe KG, Rassenti LZ, Spector LG, Strom SS, Vachon CM, Weinberg JB, Holly EA, Chanock S, Smith MT, Bracci PM, Skibola CF. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010 Aug; 42: (8)661-4.
     View PubMed
217. Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, Nowakowski GS. Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. Leuk Lymphoma. 2010 Jul; 51 (7):1233-40
     View PubMed
218. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, Jelinek DF, Grever MR, Zent CS, Call TG, Shanafelt TD. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer. 2010 May 1; 116 (9):2180-7
     View PubMed
219. Slager SL, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti L, Leis JF, Camp NJ, Kay NE, Vachon CM, Glenn M, Weinberg JB, Rabe KG, Cunningham JM, Achenbach SJ, Hanson CA, Marti GE, Call TG, Caporaso NE, Cerhan JR. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2010 Apr; 19 (4):1098-102 Epub 2010 Mar 23
     View PubMed
220. Bowen DA, Call TG, Shanafelt TD, Kay NE, Schwager SM, Reinalda MS, Rabe KG, Slager SL, Zent CS. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk Lymphoma. 2010 Apr; 51 (4):620-7
     View PubMed
221. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010 Mar 4; 115 (9):1755-64 Epub 2009 Dec 17
     View PubMed
222. Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010 Mar; 23 (1):47-59
     View PubMed
223. Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol. 2010 Feb; 148 (4):544-50 Epub 2009 Nov 06
     View PubMed
224. Dronca RS, Jevremovic D, Hanson CA, Rabe KG, Shanafelt TD, Morice WG, Call TG, Kay NE, Collins CS, Schwager SM, Slager SL, Zent CS. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry B Clin Cytom. 2010; 78 Suppl 1:S35-41
     View PubMed
225. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jager U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50. Epub 2009 Sep 17.
     View PubMed
226. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol. 2009 Nov; 147 (4):471-83 Epub 2009 Sept 08
     View PubMed
227. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res. 2009 Nov; 33 (11):1485-9 Epub 2009 Feb 24
     View PubMed
228. Rahmatpanah FB, Carstens S, Hooshmand SI, Welsh EC, Sjahputera O, Taylor KH, Bennett LB, Shi H, Davis JW, Arthur GL, Shanafelt TD, Kay NE, Wooldridge JE, Caldwell CW. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics. 2009 Oct; 1(1):39-61.
     View PubMed
229. Shanafelt TD, Byrd JC, LaPLant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2009 Sep; 146 (6):660-4 Epub 2009 July 10
     View PubMed
230. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, Jenkins G, Jelinek DF, Morice WG, Boysen J, Schwager S, Bowen D, Slager SL, Hanson CA. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009 Aug 20; 27 (24):3959-63 Epub 2009 July 20
     View PubMed
231. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009 Aug 10; 27 (23):3808-14 Epub 2009 May 26
     View PubMed
232. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009 Aug; 50 (8):1261-8
     View PubMed
233. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009 Jul 30; 114(5):957-64. Epub 2009 May 4
     View PubMed
234. Lamanna N, Kay NE. Pentostatin treatment combinations in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2009 Jun; 7(6):386-92.
     View PubMed
235. Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol. 2009 Jun; 145 (5):614-23 Epub 2009 Mar 30
     View PubMed
236. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009 May 28; 113 (22):5568-74 Epub 2009 Mar 31
     View PubMed
237. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 2009 Apr 30; 113 (18):4188-96 Epub 2008 Nov 17
     View PubMed
238. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol. 2009 Apr 10; 27 (11):1844-9 Epub 2009 Mar 02
     View PubMed
239. Kay NE, Shanafelt TD, Call TG, Wu W, Laplant BR. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2009 Apr; 50 (4):588-92
     View PubMed
240. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009 Mar; 33(3):368-76. Epub 2008 Jul 21.
     View PubMed
241. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res. 2009 Feb 15; 15 (4):1250-8
     View PubMed
242. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res. 2009 Feb; 33 (2):263-70 Epub 2008 July 25
     View PubMed
243. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood. 2009 Jan 15; 113(3):535-7. Epub 2008 Nov 13.
     View PubMed
244. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15; 115 (2):363-72
     View PubMed
245. Slager SL, Kay NE. Familial chronic lymphocytic leukemia: what does it mean to me? Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S194-7
     View PubMed
246. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res. 2008 Dec; 32 (12):1849-56 Epub 2008 June 27
     View PubMed
247. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG, Habermann TM, Ansell SM, Slager SL. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17 (11):3161-9
     View PubMed
248. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008 Oct 15; 113 (8):2110-8
     View PubMed
249. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 1; 112(5):1923-30. Epub 2008 Jun 24.
     View PubMed
250. Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leuk Res. 2008 Sep; 32 (9):1458-61 Epub 2008 Jan 07
     View PubMed
251. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15; 111(10):5101-8. Epub 2008 Mar 07.
     View PubMed
252. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol. 2008 May; 141 (5):607-14 Epub 2008 Apr 01
     View PubMed
253. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol. 2008 May; 141 (5):615-21 Epub 2008 Mar 27
     View PubMed
254. Nabhan C, Shanafelt TD, Kay NE. Controversies in the front-line management of chronic lymphocytic leukemia. Leuk Res. 2008 May; 32(5):679-88. Epub 2008 Jan 11.
     View PubMed
255. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008 Mar; 140 (5):537-46
     View PubMed
256. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol. 2008; 3:16. Epub 2008 Apr 18.
     View PubMed
257. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, Bowen D, Kay N, Shanafelt T. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008 Jan; 49 (1):49-56
     View PubMed
258. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest. 2008 Jan; 118 (1):306-15
     View PubMed
259. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood. 2007 Dec 15; 110 (13):4455-63 Epub 2007 Sept 07
     View PubMed
260. Slager SL, Kay NE, Fredericksen ZS, Wang AH, Liebow M, Cunningham JM, Vachon CM, Call TG, Cerhan JR. Susceptibility genes and B-chronic lymphocytic leukaemia. Br J Haematol. 2007 Dec; 139(5):762-71.
     View PubMed
261. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007 Dec; 48 (12):2412-7
     View PubMed
262. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res. 2007 Dec; 31(12):1737-40. Epub 2007 Jul 19.
     View PubMed
263. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007 Nov; 139 (3):398-404
     View PubMed
264. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007 Oct; 139(2):255-64.
     View PubMed
265. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007 Sep; 21(9):1885-91. Epub 2007 Jun 14.
     View PubMed
266. Zent CS, Kay NE. Chronic lymphocytic leukemia: biology and current treatment. Curr Oncol Rep. 2007 Sep; 9 (5):345-52
     View PubMed
267. Ougolkov AV, Bone ND, Fernandez-Zapico ME, Kay NE, Billadeau DD. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007 Jul 15; 110 (2):735-42 Epub 2007 Apr 26
     View PubMed
268. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res. 2007 Jul; 31 (7):899-906 Epub 2007 Jan 22
     View PubMed
269. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007 Jun 1; 109(11):2291-8.
     View PubMed
270. Mukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE, Mukhopadhyay D. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. J Nanobiotechnology. 2007 May 8; 5:4 Epub 2007 May 08
     View PubMed
271. Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc. 2007 Apr; 82 (4):449-53
     View PubMed
272. Martin W, Abraham R, Shanafelt T, Clark RJ, Bone N, Geyer SM, Katzmann JA, Bradwell A, Kay NE, Witzig TE. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res. 2007 Apr; 149 (4):231-5
     View PubMed
273. Kay NE, Shanafelt TD. Prognostic factors in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Feb; 2 (1):49-55
     View PubMed
274. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan 15; 109 (2):405-11 Epub 2006 Sept 28
     View PubMed
275. Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program. 2007; 324-31.
     View PubMed
276. Kay NE, Rai KR, O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol. 2006 Nov; 4 (11 Suppl 22):1-10; quiz 11-2
     View PubMed
277. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, Gertz MA, Dispenzieri A, Lacy M, Kyle RA, Greipp PR, Tschumper RC, Fonseca R, Bergsagel PL. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006 Oct 15; 108 (8):2755-63 Epub 2006 June 27
     View PubMed
278. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006 Oct 1; 24(28):4634-41.
     View PubMed
279. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med. 2006 Sep 19; 145 (6):435-47
     View PubMed
280. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Sep; 47 (9):1738-46
     View PubMed
281. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep; 5 (9):2378-87
     View PubMed
282. Shanafelt T, Kay N. T-cell abnormalities in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Jul; 47 (7):1197-8
     View PubMed
283. Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006 Jun; 167(2):177-81.
     View PubMed
284. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006 Jun; 30 (6):707-12 Epub 2005 Dec 01
     View PubMed
285. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, Greipp PR. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer. 2006 May 1; 106(9):1958-66.
     View PubMed
286. Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald GW. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2006 Apr 15; 166(2):152-6.
     View PubMed
287. Kay NE. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S50-4.
     View PubMed
288. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol. 2006 Apr; 33(2):174-85.
     View PubMed
289. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol. 2006 Feb 20; 24(6):983-7. Epub 2006 Jan 23.
     View PubMed
290. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia. 2005 Dec; 19 (12):2264-72
     View PubMed
291. Kay NE, Bone ND, Lee YK, Jelinek DF, Leland P, Battle TE, Frank DA, Puri RK. A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. Leuk Res. 2005 Sep; 29(9):1009-18.
     View PubMed
292. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, Schleinitz TA, Caporaso N. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005 Aug; 130(3):325-32.
     View PubMed
293. Nowakowski GS, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, Smoley SA, Remstein ED, Phyliky RL, Call TG, Shanafelt TD, Kay NE, Zent CS. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol. 2005 Jul; 130 (1):36-42
     View PubMed
294. Barnidge DR, Jelinek DF, Muddiman DC, Kay NE. Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents. J Proteome Res. 2005 Jul-Aug; 4 (4):1310-7
     View PubMed
295. Nolz JC, Tschumper RC, Pittner BT, Darce JR, Kay NE, Jelinek DF. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia. 2005 Jun; 19(6):1018-24.
     View PubMed
296. Barnidge DR, Tschumper RC, Jelinek DF, Muddiman DC, Kay NE. Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5; 819(1):33-9.
     
297. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 2005 Apr; 19: (4)513-23.
     View PubMed
298. Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM, Shanafelt TD, Lee YK, Jelinek DF, Kay NE, Dewald GW. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res. 2005 Mar; 29(3):253-62.
     View PubMed
299. Shanafelt TD, Lee YK, Bone ND, Strege AK, Narayanan VL, Sausville EA, Geyer SM, Kaufmann SH, Kay NE. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood. 2005 Mar 1; 105 (5):2099-106 Epub 2004 Sept 23
     View PubMed
300. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep. 2004 Sep; 6 (5):348-54
     View PubMed
301. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26; 351(9):893-901.
     View PubMed
302. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004 Aug 1; 104 (3):788-94 Epub 2004 Mar 02
     View PubMed
303. Ghobrial IM, Bone ND, Stenson MJ, Novak A, Hedin KE, Kay NE, Ansell SM. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc. 2004 Mar; 79 (3):318-25
     View PubMed
304. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004 Feb 15; 103 (4):1202-10 Epub 2003 Oct 23
     View PubMed
305. Zent CS, Kay NE. Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2004 Feb; 2 (2):107-13
     View PubMed
306. Oken MM, Lee S, Kay NE, Knospe W, Cassileth PA. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma. 2004 Jan; 45(1):79-84.
     View PubMed
307. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 2003 Dec 15; 102 (13):4512-9 Epub 2003 Aug 14
     View PubMed
308. Kay NE, Pittner BT. IL-4 biology: impact on normal and leukemic CLL B cells. Leuk Lymphoma. 2003 Jun; 44 (6):897-903
     View PubMed
309. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, James CD, Jelinek DF, Tschumper RC, Hanson CA, Pruthi RK, Witzig TE, Call TG, Kay NE. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003 Apr; 121 (2):287-95
     View PubMed
310. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res. 2003 Mar; 1 (5):346-61
     View PubMed
311. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood. 2002 Oct 15; 100 (8):2973-9
     View PubMed
312. Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, Sellers TA, Folsom AR. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol. 2002 Sep 15; 156 (6):527-35
     View PubMed
313. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002 May 15; 99 (10):3735-41
     View PubMed
314. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002 May; 16 (5):911-9
     View PubMed
315. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Blood EA, Rajkumar SV, Kay NE, Van Ness B, Greipp PR. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study. Cancer Res. 2002 Feb 1; 62(3):715-20.
     View PubMed
316. Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2002; 193-213
     View PubMed
317. Jelinek DF, Tschumper RC, Geyer SM, Bone ND, Dewald GW, Hanson CA, Stenson MJ, Witzig TE, Tefferi A, Kay NE. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001 Dec; 115 (4):854-61
     View PubMed
318. Kay NE, Leong TL, Bone N, Vesole DH, Greipp PR, Van Ness B, Oken MM, Kyle RA. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood. 2001 Jul 1; 98 (1):23-8
     View PubMed
319. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia. 2001 Jun; 15 (6):981-6
     View PubMed
320. Kay NE, Jelinek DF, Peterson L. Angiogenesis in B-chronic lymphocytic leukemia. Leuk Res. 2001 Jun; 25 (6):485-6
     View PubMed
321. Kay NE, Han L, Bone N, Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol. 2001 Mar; 112 (3):760-7
     View PubMed
322. Hogan WJ, Kay NE. 87-year-old man with macrocytic anemia. Mayo Clin Proc. 2001 Feb; 76(2):201-4.
     View PubMed
323. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000 Aug; 14(8):1414-8.
     View PubMed
324. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol. 2000 Apr; 109(1):24-9.
     View PubMed
325. Oken MM, Leong T, Lenhard RE Jr, Greipp PR, Kay NE, Van Ness B, Keimowitz RM, Kyle RA. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer. 1999 Sep 15; 86(6):957-68.
     View PubMed
326. Greipp PR, Trendle MC, Leong T, Oken MM, Kay NE, Van Ness B, Kyle RA. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma. 1999 Sep; 35 (1-2):83-9
     View PubMed
327. Trendle MC, Leong T, Kyle RA, Katzmann JA, Oken MM, Kay NE, Van Ness BG, Greipp PR. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486. Am J Hematol. 1999 Aug; 61 (4):232-7
     View PubMed
328. Orel SG, Kay N, Reynolds C, Sullivan DC. BI-RADS categorization as a predictor of malignancy. Radiology. 1999 Jun; 211(3):845-50.
     View PubMed
329. Kay N, Leong T, Kyle RA, Greipp P, Van Ness B, Bone N, Oken MM. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma. 1999 Mar; 33(1-2):127-33.
     View PubMed
330. Mu XY, Gosland MP, Bartik MM, Schimmelpfennig J, Kay NE. Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression. Journal of Clinical Immunology. 1999; 19(4):239-46.
     View PubMed
331. Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol. 1998 Nov; 59(3):223-9.
     View PubMed
332. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, Oken MM, Kay NE, Van Ness B, Kyle RA. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998 Apr 1; 91 (7):2501-7
     View PubMed
333. Kay NE, Leong T, Bone N, Kyle RA, Greipp PR, Van Ness B, Oken MM. T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. Br J Haematol. 1998 Mar; 100(3):459-63.
     View PubMed
334. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol. 1998 Feb; 25(1):27-33.
     View PubMed
335. Kay NE, Leong T, Kyle RA, Greipp P, Billadeau D, Van Ness B, Bone N, Oken MM. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood. 1997 Jul 1; 90(1):340-5.
     View PubMed
336. Mu X, Kay NE, Gosland MP, Jennings CD. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol. 1997 Mar; 96(4):733-5.
     View PubMed
337. Kroft SH, Finn WG, Kay NE, Peterson LC. Isolated 13q14 abnormalities and normal karyotypes are associated with typical lymphocyte morphology in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 1997 Mar; 107(3):275-82.
     View PubMed
338. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996 Oct 1; 88(7):2699-706.
     View PubMed
339. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15; 87(12):4990-7.
     View PubMed
340. Kay NE. Clinical utility of molecular probes in lymphoproliferative disorders. Blood Rev. 1996 Jun; 10(2):81-8.
     View PubMed
341. Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, Gregory SA, Spiegel RJ, Oconnell MJ. Complete remission induction with combined VBCMP chemotherapy and interferon (rIFN(alpha-2B)) in patients with multiple myeloma. Leuk Lymphoma. 1996 Feb; 20(5-6):447-452.
     View PubMed
342. Kay NE, Ranheim EA, Peterson LC. Tumor suppressor genes and clonal evolution in B-CLL. Leukemia & Lymphoma. 1995 Jun; 18(1-2):41-9.
     View PubMed
343. Kay NE, Oken MM, Kyle R, Van Ness B, Kalish L, Leong T, Greipp P. Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. Leukemia & Lymphoma. 1995 Jan; 16(3-4):351-4.
     View PubMed
344. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clinical & Diagnostic Laboratory Immunology. 1994 Jul; 1(4):365-72.
     View PubMed
345. Burton J, Kay NE. Does IL-2 receptor expression and secretion in chronic B-cell leukemia have a role in down-regulation of the immune system? Leukemia. 1994 Jan; 8(1):92-6.
     View PubMed
346. Hings I, Kay NE, Ranheim E, Seroogy C, Parson RE. Malignant B cell CD5 membrane phenotype and B cell colony growth in vivo and in vitro in patients with B-chronic lymphocytic leukemia: analysis with clinical parameters. Leukemia & Lymphoma. 1993 Dec; 12(1-2):59-67.
     View PubMed
347. Christie DJ, Sauro SC, Fairbanks KD, Kay NE. Detection of clonal platelet antibodies in immunologically-mediated thrombocytopenias: association with circulating clonal/oligoclonal B cells. Br J Haematol. 1993 Oct; 85(2):277-84.
     View PubMed
348. Kay NE, Suen R, Ranheim E, Peterson LC. Confirmation of Rb gene defects in B-CLL clones and evidence for variable predominance of the Rb defective cells within the CLL clone. Br J Haematol. 1993 Jun; 84(2):257-64.
     View PubMed
349. Billadeau D, Quam L, Thomas W, Kay N, Greipp P, Kyle R, Oken MM, Van Ness B. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992 Oct 1; 80(7):1818-24.
     View PubMed
350. Zaknoen SL, Christian SL, Suen R, Van Ness B, Kay NE. B-chronic lymphocytic leukemia cells contain both endogenous kappa immunoglobulin mRNA and critical immunoglobulin gene activation transcription factors. Leukemia. 1992 Jul; 6(7):675-9.
     View PubMed
351. Peterson LC, Lindquist LL, Church S, Kay NE. Frequent clonal abnormalities of chromosome band 13q14 in B-cell chronic lymphocytic leukemia: multiple clones, subclones, and nonclonal alterations in 82 midwestern patients. Genes, Chromosomes & Cancer. 1992 Jun; 4(4):273-80.
     View PubMed
352. Redmon B, Pyzdrowski KL, Elson MK, Kay NE, Dalmasso AP, Nuttall FQ. Hypoglycemia due to an insulin-binding monoclonal antibody in multiple myeloma. N Engl J Med. 1992 Apr 9; 326(15):994-8.
     View PubMed
353. Billadeau D, Blackstadt M, Greipp P, Kyle RA, Oken MM, Kay N, Van Ness B. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. Blood. 1991 Dec 1; 78(11):3021-9.
     View PubMed
354. Juliusson G, Gahrton G, Oscier D, Fitchett M, Ross F, Brito-Babapulle V, Catovsky D, Knuutila S, Elonen E, Lechleitner M, Tanzer J, Schoenwald M, Castoldi GL, Cuneo A, Nowell P, Peterson L, Kay NE. Cytogenetic finding and survival in B-cell chronic lymphocytic leukemia. second IWCCL compilation of data on 662 patients. Leuk Lymphoma. 1991; (Suppl):21-5.
     
355. Kay NE, Peterson L. Heterogeneity of CD5 membrane expression on B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 1991; 5:49-55.
     
356. Zaknoen SL, Kay NE. Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev. 1990 Sep; 4(3):165-74.
     View PubMed
357. Kay NE, Morley JE, Allen JI. Interaction between endogenous opioids and IL-2 on PHA-stimulated human lymphocytes. Immunology. 1990 Aug; 70(4):485-91.
     View PubMed
358. Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood. 1990 Jul 15; 76(2):401-8.
     View PubMed
359. Kay NE, Bone N, Hupke M, Dalmasso AP. Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male. Blood. 1990 May 15; 75(10):2024-9.
     View PubMed
360. Kay NE. Immune regulation of myeloma cells. Clinical Immunology Newsletter. 1990; 10(6):79.
     
361. Oken MM, Kyle RA, Kay NE, Greiipp PR, O'connell MJ. Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study. Leuk Lymphoma. 1990; 1 (2):95-100
     View PubMed
362. Verfaillie C, Miller W, Kay N, McGlave P. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Blood. 1989 Aug 1; 74(2):793-7.
     View PubMed
363. Perri RT, Kay NE. Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation. Am J Hematol. 1989 Jul; 31(3):166-72.
     View PubMed
364. Kay NE, Perri RT. Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia down-regulate B-cell immunoglobulin synthesis. Blood. 1989 Mar; 73(4):1016-9.
     View PubMed
365. Burton JD, Weitz CH, Kay NE. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol. 1989 Feb; 30(2):61-7.
     View PubMed
366. Mandel JS, Berlinger NT, Kay N, Connett J, Reape M 3rd. Organophosphate exposure inhibits non-specific esterase staining in human blood monocytes. Am J Ind Med. 1989; 15(2):207-12.
     View PubMed
367. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Oken MM, Schiffer CA, Keating MJ, Boldt DH, Kempin SJ, et al. Chronic lymphocytic leukemia: recommendations. Annals of Internal Medicine ,. 1989; 110: (8)664-5.
     
368. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov; 29(3):152-63.
     View PubMed
369. Mladenovic J, Kay NE. Erythropoietin induces rapid increases in intracellular free calcium in human bone marrow cells. J Lab Clin Med. 1988 Jul; 112(1):23-7.
     View PubMed
370. Kay NE, Perri RT. Immunobiology of malignant B cells and immunoregulatory cells in B-chronic lymphocytic leukemia. Clin Lab Med. 1988 Mar; 8(1):163-77.
     View PubMed
371. Cavanaugh J, Kay NE, Binimelis J, de Leiva A, Barbosa J. A new marker of T lymphocyte activation in type I diabetes. Adv Exp Med Biol. 1988; 246:79-84.
     View PubMed
372. Kay NE, Oken MM, Mazza JJ, Bradley EC. Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2. Nouv Rev Fr Hematol. 1988; 30(5-6):475-8.
     
373. Kay NE, Perri RT. Natural killer function in B-chronic lymphocytic leukemia. Nouv Rev Fr Hematol. 1988; 30(5-6):343-5.
     
374. Kay NE, Burton J, Wagner D, Nelson DL. The malignant B cells from B-chronic lymphocyti leukemia patients release TAC-soluble interleukin-2 receptors. Blood. 1988; 72(2):447-50.
     View PubMed
375. Morley JE, Kay NE, Solomon GF, Plotnikoff NP. Neuropeptides: conductors of the immune orchestra. Life Sci. 1987 Aug 3; 41(5):527-44.
     View PubMed
376. Kay NE, Raij L. Differential effect of hemodialysis membranes on human lymphocyte natural killer function. Artif Organs. 1987 Apr; 11(2):165-7.
     View PubMed
377. Allen JI, Syropoulos HJ, Grant B, Eagon JC, Kay NE. Cimetidine modulates natural killer cell function of patients with chronic lymphocytic leukemia. Journal of Laboratory & Clinical Medicine. 1987 Apr; 109(4):396-401.
     View PubMed
378. Kay N, Morley JE, van Ree JM. Enhancement of human lymphocyte natural killing function by non-opioid fragments of beta-endorphin. Life Sci. 1987 Mar 16; 40(11):1083-7.
     View PubMed
379. Kay NE, Zarling J. Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. Am J Hematol. 1987 Feb; 24(2):161-7.
     View PubMed
380. Raij L, Kay NE. Effect of hemodialysis membranes on human lymphocyte natural killer function. Contrib Nephrol. 1987; 59:17-25.
     View PubMed
381. Perri RT, Kay NE. Malignant chronic lymphocytic leukemia B cells express interleukin-2 receptors but fail to respond to interleukin-2's proliferative signal. Leukemia. 1987; 1(2):127-30.
     View PubMed
382. Perri RT, Wilson BS, Kay NE. Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2). Eur J Immunol. 1986 Apr; 16(4):350-5.
     View PubMed
383. Allen JI, Ferrone S, Boue D, Kay NE. The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural cell-mediated cytotoxicity. J Immunol. 1986 Mar 15; 136(6):2318-22.
     View PubMed
384. Kay NE, Kaplan ME. Defective T cell responsiveness in chronic lymphocytic leukemia: analysis of activation events. Blood. 1986 Mar; 67(3):578-81.
     View PubMed
385. O'Connell MJ, Colgan JP, Oken MM, Ritts RE Jr, Kay NE, Itri LM. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1986 Feb; 4(2):128-36.
     View PubMed
386. Grant BW, Platt JL, Jacob HS, Kay NE. Lymphocyte populations and TAC-antigen in diffuse B-cell lymphomas. Leuk Res. 1986; 10(11):1271-8.
     View PubMed
387. Kay NE. Natural killer cells. Crit Rev Clin Lab Sci. 1986; 22(4):343-59.
     View PubMed
388. Ascensao JL, Kay NE, Wright JJ, Arthur D, Finkel B, Rydell R, Kaplan ME. Lymphoblastic transformation of myelodysplastic syndrome. American Journal of Hematology. 1986; 22(4):431-4.
     View PubMed
389. Kay N, Markham PD. Chronic Lymphocytic Leukemia: an AIDS like disease? British Journal of Haematology. 1986; 63(2):389-91.
     View PubMed
390. Perri RT, Kay NE. Abnormal T cell function in early-stage chronic lymphocytic leukemia (CLL) patients. American J of Hematology ,. 1986; 22: (1)55-61.
     
391. Kay NE, Raij LR. Immune abnormalities in renal failure and hemodialysis. Blood Purif. 1986; 4(1-3):120-9.
     View PubMed
392. Wilson BS, Platt JL, Kay NE. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood. 1985 Oct; 66(4):824-9.
     View PubMed
393. Hammerschmidt DE, Goldberg R, Raij L, Kay NE. Leukocyte abnormalities in renal failure and hemodialysis. Semin Nephrol. 1985 Jun; 5(2):91-103.
     View PubMed
394. Ibele GM, Kay NE, Johnson GJ, Jacob HS. Human platelets exert cytotoxic effects on tumor cells. Blood. 1985 May; 65(5):1252-5.
     View PubMed
395. McClain K, Warkentin P, Kay N. Spontaneous remission of Burkitt's lymphoma associated with herpes zoster infection. Am J Pediatr Hematol Oncol. 1985 Spring; 7(1):9-14.
     View PubMed
396. Kay NE, Oken MM, Ascensao J, Kaplan ME. Lymphocytotoxic T lymphocytes in a patient with B-chronic lymphocytic leukemia and pure red cell aplasia. Leuk Res. 1985; 9(9):1189-94.
     View PubMed
397. Morley JE, Kay N, Allen J, Moon T, Billington CJ. Endorphins, immune function, and cancer. Psychopharmacol Bull. 1985; 21(3):485-8.
     View PubMed
398. Perri RT, Allen JI, Oken MM, Limas C, Kay NE. Simultaneous presentation of relapsing Hodgkin's disease and treatment-related non-Hodgkin's lymphoma. Medical & Pediatric Oncology. 1985; 13(3):122-5.
     View PubMed
399. Kay N, Allen J, Morley JE. Endorphins stimulate normal human peripheral blood lymphocyte natural killer activity. Life Sci. 1984 Jul 2; 35(1):53-9.
     View PubMed
400. Kay NE, Kaplan ME. Defective expression of T cell antigens in chronic lymphocytic leukaemia: relationship to T cell dysfunction. Br J Haematol. 1984 May; 57(1):105-11.
     View PubMed
401. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984 Feb; 63(2):305-9.
     View PubMed
402. Peacock TE, Kay NE, Ascensao JL, Kaplan ME. Establishment and characterization of a subclone (U-937-AG) from a permanent human monocyte cell line. Leuk Res. 1984; 8(3):435-9.
     View PubMed
403. Kay NE, Oken MM, Perri RT. The influential T cell in B-cell neoplasms. J Clin Oncol. 1983 Dec; 1(12):810-6.
     View PubMed
404. Perri RT, Royston I, LeBien TW, Kay NE. Chronic lymphocytic leukemia progenitor cells carry the antigens T65, BA-1, and Ia. Blood. 1983 May; 61(5):871-5.
     View PubMed
405. Kay NE, Johnson J, Douglas SD. Effects of human T-cell subpopulations on B-cell proliferation as determined by (3H)-thymidine incorporation. Diagn Immunol. 1983; 1(1):11-6.
     View PubMed
406. Zarling JM, Kay NE, Grant B, Yasukawa M, Bach FH. Human anti-lymphoma responses generated in vitro and in vivo following sensitization with allogeneic leukocytes. Cancer Immunol Immunother. 1983; 15(3):237-9.
     View PubMed
407. Allen JI, Perri RT, McClain CJ, Kay NE. Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. J Lab Clin Med. 1983; 102(4):577-89.
     View PubMed
408. Allen JI, Korchik W, Kay NE, McClain CJ. Zinc and T-lymphocyte function in hemodialysis patients. Am J Clin Nutr. 1982 Sep; 36(3):410-5.
     View PubMed
409. Perri RT, Kay NE, McCarthy J, Vessella RL, Jacob HS, Furcht LT. Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity. Blood. 1982 Aug; 60(2):430-5.
     View PubMed
410. Kay NE, Holloway DE, Hutton SW, Bone ND, Duane WC. Human T-cell function in experimental ascorbic acid deficiency and spontaneous scurvy. Am J Clin Nutr. 1982 Jul; 36(1):127-30.
     View PubMed
411. Perri RT, Oken MM, Kay NE. Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma. Journal of Laboratory & Clinical Medicine. 1982 Apr; 99(4):512-9.
     View PubMed
412. Perri RT, Kay NE. Monoclonal CLL B-cells may be induced to grow in an in vitro B-cell colony assay system. Blood. 1982 Feb; 59(2):247-9.
     View PubMed
413. Wilson BS, Kay NE, Imai K, Ferrone S. Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera. Cancer Immunol Immunother. 1982; 13(1):69-74.
     View PubMed
414. Kay NE, Howe RB, Douglas SD. Effect of therapy on T cell subpopulations in patients with chronic lymphocytic leukemia. Leuk Res. 1982; 6(3):345-8.
     View PubMed
415. Imai K, Natali PG, Kay NE, Wilson BS, Ferrone J. Tissue distribution and molecular profile of a differentiation antigen detected by a monoclonal antibody (345-1345) produced against human melanoma cells. Cancer Immunol Immunother. 1982; 12:159-166.
     
416. Oken MM, Kay NE. T-cell subpopulations in multiple myeloma: correlation with clinical disease status. Br J Haematol. 1981 Dec; 49(4):629-34.
     View PubMed
417. LeMarbre P, Rinehart JJ, Kay NE, Vesella R, Jacob HS. Lysozyme enhances monocyte-mediated tumoricidal activity: a potential amplifying mechanism of tumor killing. Blood. 1981 Nov; 58(5):994-9.
     View PubMed
418. Allen JI, Kay NE, McClain CJ. Severe zinc deficiency in humans: association with a reversible T-lymphocyte dysfunction. Ann Intern Med. 1981 Aug; 95(2):154-7.
     View PubMed
419. Ascensao JL, Kay NE, Banisadre M, Zanjani ED. Cell-cell interaction in human granulopoiesis: role of T lymphocytes. Exp Hematol. 1981 May; 9(5):473-8.
     View PubMed
420. Ziegler HW, Kay NE, Zarling JM. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer. 1981 Mar 15; 27(3):321-7.
     View PubMed
421. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood. 1981 Mar; 57(3):418-20.
     View PubMed
422. Kay NE, Douglas SD. Detection of shedding of human blood monocyte Fc receptor during in vitro culture. International Archives of Allergy & Applied Immunology. 1981; 66(2):131-5.
     View PubMed
423. Ascensao JL, Kay NE, Earenfight-Engler T, Koren HS, Zanjani ED. Production of erythroid potentiating factor(s) by a human monocytic cell line. Blood. 1981 Jan; 57(1):170-3.
     View PubMed
424. Zuckerman SH, Kay NE, Douglas SD. Effect of adenosine deaminase inhibitors on Fc mu receptor expression in human T-cell cultures. Cell Immunol. 1980 Nov; 56(1):112-9.
     View PubMed
425. Kay NE, Bumol TF, Douglas SD. Effects of 2-deoxy-D-glucose on human monocyte metabolism and function. J Reticuloendothel Soc. 1980 Oct; 28(4):367-79.
     View PubMed
426. Kay NE, Ackerman SK, Douglas SD. Anatomy of the immune system. Semin Hematol. 1979 Oct; 16(4):252-82.
     View PubMed
427. Kay NE, Douglas SD, Nelson RD. Human neutrophil migratory function: modulatory effect of interactions with opsonized particles. Infection & Immunity. 1979 Oct; 26(1):12-4.
     View PubMed
428. Kay NE, Johnson JD, Stanek R, Douglas SD. T-cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in vitro receptor maturation. Blood. 1979 Aug; 54(2):540-4.
     View PubMed
429. Kay NE, Douglas SD. Monocyte metabolic activation in patients with rheumatoid arthritis. Experimental Biology & Medicine. 1979 Jul; 161(3):303-6.
     View PubMed
430. Kay NE, Ackerman SK, Douglas SD. Detachment of adherent human monocytes from glass surfaces induced by antibody-coated and uncoated erythrocytes. Clinical Immunology & Immunopathology. 1979 Jul; 13(3):269-6.
     View PubMed
431. Gordon LI, Douglas SD, Kay NE, Yamada O, Osserman EF, Jacob HS. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest. 1979 Jul; 64(1):226-32.
     View PubMed
432. Harris RD, Kay NE, Seljeskog EL, Murray KJ, Douglas SD. Prolactin suppression of leukocyte chemotaxis in vitro. J Neurosurg. 1979 Apr; 50(4):462-5.
     View PubMed
433. Smith JR, Kay NE, Gottlieb AJ, Oski FA. Abnormal erythrocyte metabolism in hepatic disease: effect of NADP repletion. Am J Hematol. 1979; 6(4):313-21.
     View PubMed
434. Gordon LI, Hrushesky W, Oken MM, Kay NE, Rydell RE. Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases. Medical & Pediatric Oncology. 1979; 7(2):111-6.
     View PubMed
435. Kay NE, Anderson K. Direct antiglobulin "Coombs'" test. Incidence of positive findings in normal population: retrospective study. N Y State J Med. 1978 Jul; 78(8):1244-6.
     View PubMed
436. Ackerman SK, Bumol TF, Kay NE, Douglas SD. Cellular immunologic studies of a patient with monocytic leukemia. Am J Med. 1978 Jun; 64(6):1061-8.
     View PubMed
437. Kay NE, Gordon LI, Douglas SD. Autoimmune hemolytic anemia in association with monoclonal IgM(kappa) with anti-i activity. Am J Med. 1978 May; 64(5):845-50.
     View PubMed
438. Kay NE, Bumol TF, Douglas SD. Effect of phagocytosis and Fc receptor occupancy on complement-dependent neutrophil chemotaxis. Journal of Laboratory & Clinical Medicine. 1978 May; 91(5):850-6.
     View PubMed
439. Murray KJ, Kay NE, Douglas SD. Blood-group antigens and antibodies in human brain-tumor cysts. J Neurosurg. 1978 Feb; 48(2):164-8.
     View PubMed
440. Handwerger BS, Kay NE, Douglas SD. Lymphocyte-mediated antibody-dependent cytolysis: role in immune hemolysis. Vox Sang. 1978; 34(5):276-80.
     View PubMed
441. Kay NE, Douglas SD. Monocyte-erythrocyte interaction in vitro in immune hemolytic anemias . Blood. 1977 Nov; 50(5):889-97.
     View PubMed
442. Kay NE, Murray KJ, Douglas SD. Neutrophil chemotaxis in cerebral astrocytoma. Surg Neurol. 1977 Oct; 8(4):255-7.
     View PubMed
443. Kay NE, Douglas SD. Mononuclear phagocyte. Development, structure, function, and involvement in immune response. N Y State J Med. 1977 Mar; 77(3):327-39.
     View PubMed
444. Douglas SD, Kay NE. Fluctuations of lymphocyte surface markers in chronic lymphocytic leukemia. N Engl J Med. 1976; 295:504-505.
     
445. Smith JR, Kay NE, Gottlieb AJ, Oski FA. Abnormal erythrocyte metabolism in hepatic disease. Blood. 1975 Dec; 46(6):955-64.
     View PubMed
446. Kay NE, Douglas SD, Mond JJ, Flier JS, Kochwa S, Rosenfield RE. Hemolytic anemia with serum and erythrocyte-bound low-molecular-weight IgM. Clinical Immunology & Immunopathology. 1975 Jul; 4(2):216-25.
     View PubMed
447. Kay NE, Douglas SD, Estren S. Letter: T-cells in chronic lymphocytic leukaemia. Lancet. 1974 Nov 30; 2(7892):1326.
     View PubMed
448. Smith JR, Kay NE. Polycythemia-1973. Laboratory and clinical evaluation. Postgrad Med. 1973 Dec; 54(6):141-4 passim.
     View PubMed
449. Kay NE, Gottlieb AJ. Hypouricemia in Hodgkin's disease. Report of an additional case. Cancer. 1973 Dec; 32(6):1508-11.
     View PubMed
450. Kay NE, Stockman JA 3rd, Stuart MJ, Gottlieb AJ, Oski FA. Letter: Asparaginase-induced megaloblastic changes. JAMA. 1973 Nov 5; 226(6):673.
     View PubMed
451. Kay NE, Nelson DA, Gottlieb AJ. Eosinophilic Pelger-Huet anomaly with myeloproliferative disorder. Am J Clin Pathol. 1973 Nov; 60(5):663-8.
     View PubMed